Date: May 17, 2010

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Introduction of Prevnar® 13 on June 1, 2010:
Revisions to the Communicable Disease Control Manual –
Chapter 2, Immunization Program

Please note the following changes to the Communicable Disease Control Manual, Chapter 2 – Immunization Program:

Section VII, Biological Products:

Table of Contents:
- Updated to reflect change from Prevnar™ to Prevnar® 13.

Page 44, “Pneumococcal Conjugate Vaccine (Prevnar® 13):”
- New page
- Offered to healthy and high risk children 2 to 59 months of age to start or complete a pneumococcal conjugate vaccine series. That is, for children who have started a pneumococcal conjugate vaccine series with a 7 or 10 valent vaccine, use Prevnar® 13 for the next and subsequent scheduled dose(s).
- Schedules for healthy and high risk infants are unchanged: 3 doses given at 2, 4 and 12 months of age for healthy infants; 4 doses given at 2, 4, 6 and 12 months of age for high risk children
- Offer one dose of Prevnar®13 for high risk children to 59 months of age who have completed a pneumococcal conjugate (7 or 10-valent) vaccine series.

Administrative Circular 2010:07
Page 45, “Pneumococcal Conjugate Vaccine (Prevnar® 13) Completing a Pneumococcal vaccine Series:”

- History of prior doses includes doses with a 7, 10 or 13 valent pneumococcal conjugate vaccine
- At 24 to 59 months of age high risk children receive 2 doses of Prevnar® 13 when 0, 1 or 2 doses of a pneumococcal conjugate vaccine were received previously.
- High risk children to 59 months of age receive one dose of Prevnar® 13 when a pneumococcal conjugate 7 or 10 valent vaccine series has been completed previously.

Page 46, “Recommendations for Pneumococcal Immunization With 13-Valent Pneumococcal Conjugate Vaccine (PCV 13) and 23-Valent Pneumococcal Polysaccharide Vaccine (PPV 23) for Children at High Risk of Pneumococcal Disease:”

- Two doses of Prevnar® 13 given when ≤2 doses given prior to 24 months of age.

On June 1, 2010 please remove and destroy the following pages from the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII:

<table>
<thead>
<tr>
<th>Table of Contents</th>
<th>Dated April 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page 44</td>
<td>Dated January 2010</td>
</tr>
<tr>
<td>Pages 45 &amp; 46</td>
<td>Dated January 2009</td>
</tr>
</tbody>
</table>

On June 1, 2010 please insert the following pages in the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII:

<table>
<thead>
<tr>
<th>Table of Contents</th>
<th>Dated June 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pages 44, 45 &amp; 46</td>
<td>Dated June 2010</td>
</tr>
</tbody>
</table>
If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist, or Cheryl McIntyre, Associate Nurse Epidemiologist, at telephone (604) 707-2510, fax (604) 707-2516 or by email at karen.pielak@bccdc.ca or cheryl.mcintyre@bccdc.ca

Sincerely,

Dr. Monika Naus,
Medical Director, Immunization Program and
Associate Medical Director, Epidemiology Services
BC Centre for Disease Control

pc: Ministry of Healthy Living and Sport:

Dr. Perry Kendall       Dr. Eric Young
Provincial Health Officer       Deputy Provincial Health Officer

Dr. Bob Fisk         Craig Thompson
Medical Consultant       Director, CD Prevention – Immunization
Non-Communicable Disease

Warren O’Briain
Executive Director
Communicable Disease and Addiction Prevention